Cervipro

/Tag:Cervipro
­

The Cervipro Project progresses towards a new vaccine against cervical cancer

The coordinators of the Cervipro Project have recently met in Bionaturis facilities in Jerez with the goal of continue progressing in the development of the vaccine. In particular, Michael Götz (from the German Company BioEnergy GmbH & Consultant) and Martin Müller and Caroline Odenwald (from German Cancer Research-DKFZ) were the attendants. From Bionaturis, Elena de la Torre (Project Manager); Felix Risco (CTO) and Juan Jose Infante (CSO) were the participants.

The aim of the Cervipro Project is the development of a cost-effective vaccine against the Human Papilomavirus, which causes cervical cancer. This project receive funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union (further information in the Relevant info published in 2015, only in Spanish)

The Cervipro Project –which started at the beginning of 2016- continues with several advances, such as the growing of the plants that will produce the vaccine and the experimental design of purification.

“Although we are in an early stage, the project is accomplishing the planned milestones. The participating companies and institutions are providing the necessary resource and Cervipro is moving towards its final goal. We are conscious that there is still a long way but we are convinced that we are in the right one”, Michael Götz, from BioEnergy GmbH & Consultant, has stated as leader of the Project.

With this project, Bionaturis Group is taking part in an alternative strategy to produce this drug in a cost-effective way, to make it affordable to the most needy regions, in other words, contributing to a global access to health. Specifically, Bionaturis Group is in charge of the development of the purification process of the vaccine as well as its analytical classification.

From Bionaturis, Elena […]

May 18th, 2017|Blog english|Comments Off on The Cervipro Project progresses towards a new vaccine against cervical cancer

El proyecto Cervipro avanza con un encuentro en Heildelberg

El proyecto destinado al desarrollo de una vacuna costo-efectiva contra el cáncer cervical, denominado Cervipro, sigue avanzando tras el encuentro celebrado la pasada semana entre  Elena de la Torre, Project Manager de Bionaturis, y los representantes del Instituto de Investigación German Cancer Research Center (DKFZ) y la empresa BioEnergy GmbH & Consultant (líderes del consorcio).

El encuentro, celebrado en la sede del centro investigador en Heildelberg (Alemania), sirvió para hacer un seguimiento de las aportaciones y acciones de cada uno de los integrantes, así como para marcar los próximos hitos en el desarrollo. Además de la representante del Grupo Bionaturis –Elena de la Torre-, los asistentes a este encuentro fueron Michael Götz (por parte de BioEnergy GmbH & Consultant), Martin Müller y Caroline Odenwald (de DKFZ).

El objetivo de Cervipro es la consecución de una vacuna costo-efectiva contra el virus del Papiloma Humano, causante del cáncer cervical o cáncer de cuello uterino. Este proyecto recibe la financiación del programa conjunto Eurostars-2 con cofinanciación de CDTI y del Programa Marco de Investigación e Innovación Horizonte 2020 de la Unión Europea.

Participando en una estrategia alternativa para producir el fármaco de manera costo-efectiva para hacerlo accesible a las regiones menos favorecidas donde se necesite, el Grupo Bionaturis responde así a su visión ‘A global Access To Health’.

Sobre Bionaturis 

El Grupo Bionaturis ofrece productos y servicios biotecnológicos de última generación para salud humana y animal. Considerada un referente internacional en el desarrollo de vacunas, el grupo biotecnológico, que tiene como visión un acceso más global a la salud, cotiza en bolsa con el ticker BNT.

February 4th, 2016|Blog español|Comments Off on El proyecto Cervipro avanza con un encuentro en Heildelberg

Bionaturis Group takes part in the development of a vaccine against cervical cancer

The Centre for the Development of Industrial Technology (CDTI, in Spanish) has granted an incentive of 184.847,40 Euros to the company from the European Programme Eurostars
The project is led by the German company BioEnergy GmbH & Consultant with participation from the German Cancer Research Center

Jerez de la Frontera, January 12nd 2016. Bionaturis Group will take part in the development of a cost-effective and possibly oral vaccine against cervical cancer. The initiative, led by the German company BioEnergy GmbH & Consultant with the participation of the German Cancer Research Center, receives funding from the Eurostars-2 Programme with co-funding from CDTI and the Research and Innovation Horizon 2020 Framework Programme from European Union.

According to the World Health Organization (WHO), developing countries suffer the highest impact from cervical cancer, which is caused by the Human Papillomavirus (HPV). Currently available vaccines are at a price point that makes them unaffordable for most people in developing countries. In addition to the loss of human lives, this circumstance leaves a large gap in the global coverage against the disease. With this project, Bionaturis Group is taking part in an alternative strategy to produce a cost-effective vaccine that will be affordable for the most highly impacted regions, following its vision of ‘A Global Access To Health’.

“This project is a real and relevant challenge for Bionaturis because, with it, we are expanding our horizons. Our acquired technological expertise in both vaccine development and cost effective manufacturing platforms lets us face this initiative with the realistic goal of providing to the population at risk a first-in-class drug that will be affordable given the social and economic conditions of their countries”, Bionaturis CSO, Juan Jose Infante, has stated.

The WHO highlights that cervical cancer caused the […]

January 12th, 2016|Blog english, Press Releases|Comments Off on Bionaturis Group takes part in the development of a vaccine against cervical cancer

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR